Genmab: Daratumumab is becoming an increasingly critical asset for JNJ

BUY-Top Picks, Fair Value DKK1170 (+39%)
News published on January Friday 29, 2016
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities